Shervin Yousefian, MD
Internal Medicine · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Bass Medical Group · 292 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yousefian’s office at (650) 967-8841 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A125229 · Current
Licensed to practise in California · since 2013 · expires 2027-04-30 · Iran Medical Centre Aka Iran University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$104,980
Medicare paid this office $104,980 for 168 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 14 | $25,803 | None |
| Return visit (30+ min) | 108 | $23,901 | $112 |
| Long return visit (40+ min) | 79 | $19,436 | $168 |
| New patient visit (60+ min) | 77 | $13,368 | $174 |
| Short return visit (20+ min) | 68 | $8,113 | $79 |
See all 10 services
| Injection, denosumab, 1 mg | 14 | $25,803 | None |
| Return visit (30+ min) | 108 | $23,901 | $112 |
| Long return visit (40+ min) | 79 | $19,436 | $168 |
| New patient visit (60+ min) | 77 | $13,368 | $174 |
| Short return visit (20+ min) | 68 | $8,113 | $79 |
| Ultrasound scan of head and neck soft tissue | 34 | $4,107 | $114 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 128 | $4,046 | $14 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 21 | $3,501 | $135 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 25 | $1,612 | $31 |
| Injection of drug or substance under skin or into muscle | 15 | $318 | $14 |
Who their Medicare patients are
168 Original Medicare patients in 2024. Average age 75 · Women 67% · Health risk score 1.04. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 65% · Diabetes 46% · Coronary heart disease 30% · Chronic kidney disease 25% · Cancer 17% · Atrial fibrillation 13% · Heart failure 11% · Depression 11% · COPD 8% · Stroke 7%.
The office billed $378,357, Medicare allowed $140,472 and paid $104,980; for 2,199 services of 15 kinds; $25,862 of it was for drugs given in the office and $79,118 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 168 | 2,199 | 75 | 1.04 | $378,357 | $104,980 |
| 2023 | 187 | 1,361 | 75 | 1.15 | $263,257 | $67,591 |
| 2022 | 166 | 264 | 72 | 1.67 | $140,591 | $16,614 |
| 2021 | 177 | 277 | 72 | 1.86 | $122,137 | $19,283 |
| 2020 | 171 | 303 | 71 | 1.93 | $134,940 | $15,959 |
| 2019 | 172 | 295 | 70 | 1.90 | $181,366 | $17,223 |
| 2018 | 158 | 293 | 69 | 1.85 | $169,581 | $16,261 |
| 2017 | 124 | 233 | 68 | 1.84 | $128,265 | $15,137 |
| 2014 | 156 | 377 | 70 | 3.00 | $112,114 | $31,434 |
| 2013 | 426 | 1,275 | 69 | 3.07 | $351,465 | $97,653 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Injection, denosumab, 1 mg | 14 | $16,460 | None |
| Return visit (30+ min) | 70 | $12,999 | $121 |
| Long return visit (40+ min) | 58 | $12,025 | $165 |
| New patient visit (60+ min) | 49 | $10,050 | $205 |
| Short return visit (20+ min) | 49 | $5,335 | $85 |
| Ultrasound scan of head and neck soft tissue | 28 | $3,403 | $122 |
| Return visit (30+ min) | 35 | $1,637 | $47 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 16 | $1,091 | $32 |
| Short return visit (20+ min) | 16 | $376 | $23 |
| Injection of drug or substance under skin or into muscle | 15 | $220 | $14 |
2022: 4 services
| Return visit (30+ min) | 92 | $9,423 | $82 |
| Short return visit (20+ min) | 64 | $4,299 | $54 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,157 | $48 |
| Short return visit | 20 | $419 | $21 |
2021: 6 services
| Telephone medical discussion with physician, 11-20 minutes | 79 | $5,790 | $56 |
| Return visit (30+ min) | 38 | $3,728 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,252 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,476 | $92 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $2,234 | $106 |
| Short return visit (20+ min) | 20 | $1,083 | $52 |
2020: 6 services
| Telephone medical discussion with physician, 21-30 minutes | 58 | $4,235 | $63 |
| Telephone medical discussion with physician, 11-20 minutes | 71 | $3,853 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $3,335 | $76 |
| Return visit (30+ min) | 58 | $2,572 | $40 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,452 | $97 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $358 | $21 |
2019: 3 services
| Return visit (30+ min) | 134 | $13,253 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,591 | $61 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,551 | $91 |
2018: 5 services
| Return visit (30+ min) | 128 | $11,594 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,896 | $65 |
| New patient visit (45+ min) | 17 | $1,153 | $68 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $988 | $90 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $109 | $6 |
2017: 2 services
| Return visit (30+ min) | 97 | $11,005 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,525 | $90 |
2014: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $17,856 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,170 | $150 |
| Hospital discharge day management, more than 30 minutes | 50 | $3,988 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,212 | $55 |
2013: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 252 | $44,902 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $15,734 | $148 |
| Hospital discharge day management, more than 30 minutes | 166 | $13,324 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 119 | $10,861 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,222 | $98 |
| Initial hospital observation care per day, typically 70 minutes | 26 | $3,564 | $132 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $2,038 | $29 |
| Hospital discharge day management, 30 minutes or less | 33 | $1,776 | $54 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 22 | $192 | $9 |
Medicaid work
$1,672 in 2023
Medicaid paid $1,672 for 117 billed services this clinician did in 2023, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 71 | $1,193 |
| Short return visit (20+ min) | 34 | $338 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 12 | $141 |
| 2023 | 117 | 3 | 30 | $1,672 |
| 2022 | 519 | 4 | 37 | $3,115 |
| 2021 | 383 | 2 | 52 | $2,454 |
| 2020 | 166 | 2 | 56 | $1,535 |
| 2019 | 630 | 4 | 65 | $3,931 |
| 2018 | 799 | 6 | 68 | $7,113 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 288 | $1,457 |
| Return visit (30+ min) | 165 | $1,074 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 39 | $496 |
| Short return visit | 27 | $88 |
2021
| Short return visit (20+ min) | 321 | $2,196 |
| Return visit (30+ min) | 62 | $258 |
2020
| Return visit (30+ min) | 150 | $1,288 |
| IP/OBS CONSLTJ NEW/EST SF 35 | 16 | $246 |
2019
| Return visit (30+ min) | 569 | $2,745 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 36 | $824 |
| Thyroid stimulating hormone (TSH) | 12 | $228 |
| Measurement of free thyroxine | 13 | $133 |
2018
| Return visit (30+ min) | 530 | $3,798 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 136 | $1,427 |
| Thyroid stimulating hormone (TSH) | 45 | $857 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 28 | $548 |
| Measurement of free thyroxine | 42 | $429 |
| Short return visit (20+ min) | 18 | $53 |
Drugs they prescribed that Part D paid
$397,634
Pharmacies billed $397,634 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 759) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
375 generic and 333 brand-name prescriptions · $397,634 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 60 | $84,940 | $1,416 |
| Trulicity | 27 | $56,615 | $2,097 |
| Ozempic | 39 | $54,988 | $1,410 |
| Mounjaro | 12 | $23,129 | $1,927 |
| Soliqua 100-33 | 21 | $22,280 | $1,061 |
See all 18 drugs
| Jardiance | 60 | $84,940 | $1,416 |
| Trulicity | 27 | $56,615 | $2,097 |
| Ozempic | 39 | $54,988 | $1,410 |
| Mounjaro | 12 | $23,129 | $1,927 |
| Soliqua 100-33 | 21 | $22,280 | $1,061 |
| Humalog Kwikpen U-100 | 11 | $8,486 | $771 |
| Synthroid | 25 | $2,517 | $101 |
| Nano 2nd Gen Pen Needle | 18 | $2,307 | $128 |
| NP Thyroid | 14 | $990 | $71 |
| Levothyroxine | 75 | $930 | $12 |
| Rosuvastatin | 27 | $747 | $28 |
| Metformin Hcl Er | 47 | $681 | $14 |
| Hydrocortisone | 12 | $580 | $48 |
| Metformin | 31 | $351 | $11 |
| Atorvastatin | 22 | $242 | $11 |
| Alendronate | 45 | $225 | $5 |
| Simvastatin | 18 | $220 | $12 |
| Methimazole | 24 | $161 | $7 |
Year by year
| 2024 | 759 | 144 | 0% (0) | 44% | $397,634 |
| 2023 | 708 | 218 | 0% (0) | 37% | $379,950 |
| 2022 | 565 | 154 | 0% (0) | 38% | $272,450 |
| 2021 | 539 | 137 | 0% (0) | 30% | $166,728 |
| 2020 | 584 | 136 | 0% (0) | 39% | $202,195 |
| 2019 | 590 | 112 | 0% (0) | 41% | $311,469 |
| 2018 | 520 | 120 | 0% (0) | 45% | $306,053 |
| 2017 | 287 | 78 | 0% (0) | 39% | $155,686 |
| 2016 | 218 | 49 | 0% (0) | None | $28,842 |
| 2015 | 167 | 45 | 0% (0) | None | $15,076 |
| 2014 | 140 | 44 | None | 25% | $9,048 |
| 2013 | 230 | 84 | 5% (12) | None | $29,089 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Tymlos | 25 | $64,764 | $2,591 |
| Trulicity | 23 | $46,693 | $2,030 |
| Prolia | 29 | $45,296 | $1,562 |
| Jardiance | 28 | $43,446 | $1,552 |
| Ozempic | 19 | $35,858 | $1,887 |
| Levothyroxine | 104 | $1,922 | $18 |
| Ultra-Fine Short Pen Needle | 22 | $1,541 | $70 |
| Alendronate | 52 | $868 | $17 |
| Metformin | 36 | $561 | $16 |
| Atorvastatin | 22 | $550 | $25 |
| Methimazole | 38 | $468 | $12 |
| Metformin Hcl Er | 22 | $362 | $16 |
| Rosuvastatin | 17 | $234 | $14 |
| Simvastatin | 13 | $127 | $10 |
| Amlodipine Besylate | 12 | $92 | $8 |
| Hydrochlorothiazide | 11 | $38 | $3 |
2022: 12 drugs
| Prolia | 75 | $103,239 | $1,377 |
| Forteo | 12 | $43,632 | $3,636 |
| Jardiance | 13 | $22,901 | $1,762 |
| Cinacalcet | 18 | $18,093 | $1,005 |
| Novolog Flexpen | 11 | $6,488 | $590 |
| Lantus Solostar | 15 | $4,361 | $291 |
| Levothyroxine | 89 | $2,521 | $28 |
| Humalog Kwikpen U-100 | 11 | $2,467 | $224 |
| Hydrocortisone | 12 | $868 | $72 |
| Methimazole | 56 | $772 | $14 |
| Alendronate | 58 | $607 | $10 |
| Atorvastatin | 19 | $451 | $24 |
2021: 12 drugs
| Prolia | 54 | $66,336 | $1,228 |
| Cinacalcet | 20 | $7,435 | $372 |
| Lantus Solostar | 11 | $2,484 | $226 |
| Levothyroxine | 92 | $2,439 | $27 |
| Hydrocortisone | 15 | $936 | $62 |
| Testosterone Cypionate | 15 | $821 | $55 |
| Alendronate | 67 | $643 | $10 |
| Methimazole | 50 | $597 | $12 |
| Metformin | 15 | $153 | $10 |
| Atorvastatin | 12 | $112 | $9 |
| Simvastatin | 11 | $62 | $6 |
| Dexamethasone | 12 | $12 | $1 |
2020: 12 drugs
| Prolia | 40 | $46,569 | $1,164 |
| Tresiba Flextouch U-200 | 17 | $32,132 | $1,890 |
| Cinacalcet | 22 | $14,075 | $640 |
| Novolog Flexpen | 12 | $13,532 | $1,128 |
| Basaglar Kwikpen U-100 | 13 | $8,080 | $622 |
| Novolog | 12 | $6,901 | $575 |
| Testosterone | 15 | $5,063 | $338 |
| Levothyroxine | 122 | $3,282 | $27 |
| Alendronate | 72 | $638 | $9 |
| Methimazole | 46 | $581 | $13 |
| Atorvastatin | 12 | $179 | $15 |
| Metformin | 18 | $143 | $8 |
2019: 10 drugs
| Forteo | 45 | $148,562 | $3,301 |
| Prolia | 49 | $57,925 | $1,182 |
| Novolog | 12 | $10,080 | $840 |
| Basaglar Kwikpen U-100 | 21 | $9,658 | $460 |
| Cinacalcet | 13 | $9,458 | $728 |
| Levothyroxine | 110 | $3,323 | $30 |
| Methimazole | 63 | $1,063 | $17 |
| Alendronate | 74 | $997 | $13 |
| Ultra-Fine Short Pen Needle | 11 | $719 | $65 |
| Metformin | 16 | $119 | $7 |
2018: 10 drugs
| Forteo | 63 | $202,692 | $3,217 |
| Prolia | 33 | $37,947 | $1,150 |
| Sensipar | 23 | $28,266 | $1,229 |
| Levothyroxine | 102 | $2,891 | $28 |
| Methimazole | 56 | $857 | $15 |
| Hydrocortisone | 15 | $734 | $49 |
| Alendronate | 54 | $569 | $11 |
| Ultra-Fine Short Pen Needle | 13 | $437 | $34 |
| Testosterone Cypionate | 12 | $371 | $31 |
| Metformin | 22 | $131 | $6 |
2017: 6 drugs
| Forteo | 38 | $110,372 | $2,905 |
| Prolia | 12 | $12,841 | $1,070 |
| Levothyroxine | 56 | $1,679 | $30 |
| Methimazole | 31 | $357 | $12 |
| Alendronate | 16 | $79 | $5 |
| Simvastatin | 12 | $50 | $4 |
2016: 3 drugs
| Synthroid | 25 | $1,578 | $63 |
| Levothyroxine | 35 | $706 | $20 |
| Alendronate | 27 | $153 | $6 |
2015: 4 drugs
| Synthroid | 13 | $677 | $52 |
| Levothyroxine | 17 | $448 | $26 |
| Hydrocortisone | 18 | $375 | $21 |
| Alendronate | 26 | $261 | $10 |
2014: 2 drugs
| Meropenem | 18 | $2,311 | $128 |
| Sodium Chloride | 18 | $102 | $6 |
2013: 3 drugs
| Metoprolol | 14 | $387 | $28 |
| Levofloxacin | 11 | $93 | $8 |
| Lisinopril | 14 | $67 | $5 |
Money from drug and device companies
$2,525 in 2025
| 2025 | 22 | 104 | None | $2,525 |
| 2024 | 20 | 93 | None | $2,399 |
| 2023 | 19 | 56 | None | $1,397 |
| 2020 | 1 | 1 | None | $147 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Evenity | $495 | 19 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $284 | 10 payments
|
| Radius Health | Tymlos | $232 | 8 payments
|
| Novo Nordisk | Wegovy | $220 | 12 payments
|
| Lilly USA | Mounjaro | $188 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $174 | 7 payments
|
See all 102 published payments
| Exact Sciences | Meals · 2025-12-17 | None | $21 |
| Lilly USA | Meals · 2025-12-16 | None | $24 |
| Madrigal Pharmaceuticals | Meals · 2025-12-16 | Rezdiffra | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-12-16 | Rezdiffra | $6 |
| Amgen | Meals · 2025-12-12 | Repatha | $22 |
| Radius Health | Meals · 2025-12-12 | Tymlos | $31 |
| Amgen | Meals · 2025-12-10 | Evenity | $11 |
| Madrigal Pharmaceuticals | Meals · 2025-12-10 | Rezdiffra | $29 |
| Novo Nordisk | Meals · 2025-12-09 | Wegovy | $27 |
| Novo Nordisk | Meals · 2025-12-08 | Wegovy | $2 |
| Amgen | Meals · 2025-12-04 | Evenity | $34 |
| Amgen | Meals · 2025-12-01 | Tepezza | $33 |
| Dexcom | Meals · 2025-11-21 | Dexcom G6 Transmitter | $25 |
| Amgen | Meals · 2025-11-18 | Repatha | $29 |
| Madrigal Pharmaceuticals | Meals · 2025-11-18 | Rezdiffra | $30 |
| Xeris Pharmaceuticals | Meals · 2025-11-14 | Recorlev | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-13 | Jardiance | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-11-13 | Rezdiffra | $31 |
| Kyowa Kirin | Meals · 2025-11-06 | Crysvita | $29 |
| Amgen | Meals · 2025-11-03 | Repatha | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-30 | Jardiance | $24 |
| Abbvie | Meals · 2025-10-27 | Synthroid | $19 |
| Novo Nordisk | Meals · 2025-10-23 | Rybelsus | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-10-21 | Rezdiffra | $23 |
| Sequel Med Tech | Meals · 2025-10-16 | Twiist | $31 |
| Amgen | Meals · 2025-10-14 | Tepezza | $29 |
| Amgen | Meals · 2025-10-09 | Evenity | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-10-08 | Rezdiffra | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-03 | Kerendia | $27 |
| Soleno Therapeutics | Meals · 2025-09-29 | Vykat Xr | $28 |
| Radius Health | Meals · 2025-09-25 | Tymlos | $34 |
| Lilly USA | Meals · 2025-09-24 | Mounjaro | $21 |
| CeQur | Meals · 2025-09-23 | Cequr Simplicity | $28 |
| CeQur | Meals · 2025-09-23 | Cequr Simplicity | $28 |
| Madrigal Pharmaceuticals | Meals · 2025-09-22 | Rezdiffra | $40 |
| Medtronic | Meals · 2025-09-17 | Minimed 780g | $33 |
| Exact Sciences | Meals · 2025-09-15 | The Cologuard Plus Collection Kit | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-11 | Jardiance | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-11 | Kerendia | $34 |
| Amgen | Meals · 2025-09-09 | Tepezza | $32 |
| Xeris Pharmaceuticals | Meals · 2025-09-08 | Gvoke Hypopen | $21 |
| Sanofi-Aventis U.S. | Meals · 2025-08-28 | Tzield | $26 |
| Madrigal Pharmaceuticals | Meals · 2025-08-26 | Rezdiffra | $38 |
| Ascendis Pharma Endocrinology | Meals · 2025-08-22 | Yorvipath | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-21 | Kerendia | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-21 | Kerendia | $0 |
| Lilly USA | Meals · 2025-08-19 | Mounjaro | $20 |
| Amgen | Meals · 2025-08-18 | Evenity | $27 |
| Alexion Pharmaceuticals | Meals · 2025-08-14 | Strensiq | $22 |
| Sequel Med Tech | Meals · 2025-08-12 | Twiist | $33 |
| Dexcom | Meals · 2025-08-12 | Dexcom G6 Transmitter | $34 |
| Sanofi-Aventis U.S. | Meals · 2025-07-31 | Tzield | $24 |
| Radius Health | Meals · 2025-07-28 | Tymlos | $21 |
| Lilly USA | Meals · 2025-07-18 | Mounjaro | $21 |
| Novo Nordisk | Meals · 2025-07-17 | Wegovy | $34 |
| Amgen | Meals · 2025-07-17 | Evenity | $34 |
| Pfizer | Meals · 2025-07-03 | Somavert | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-26 | Jardiance | $32 |
| Ascendis Pharma Endocrinology | Meals · 2025-06-24 | Yorvipath | $30 |
| Novo Nordisk | Meals · 2025-06-23 | Wegovy | $7 |
| Mannkind | Meals · 2025-06-18 | Afrezza | $41 |
| Radius Health | Meals · 2025-06-16 | Tymlos | $33 |
| Lilly USA | Meals · 2025-06-04 | Mounjaro | $17 |
| Novo Nordisk | Meals · 2025-06-02 | Ozempic | $20 |
| Novo Nordisk | Meals · 2025-05-24 | Wegovy | $5 |
| Novo Nordisk | Meals · 2025-05-23 | Rybelsus | $25 |
| Novo Nordisk | Meals · 2025-05-23 | Wegovy | $7 |
| Soleno Therapeutics | Meals · 2025-05-19 | Vykat Xr | $18 |
| Radius Health | Meals · 2025-05-16 | Tymlos | $33 |
| Dexcom | Meals · 2025-05-13 | Dexcom G6 Transmitter | $23 |
| Sanofi-Aventis U.S. | Meals · 2025-05-08 | Tzield | $25 |
| Lilly USA | Meals · 2025-05-07 | Mounjaro | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-05-05 | Rezdiffra | $31 |
| Amgen | Meals · 2025-05-01 | Evenity | $22 |
| Novo Nordisk | Meals · 2025-04-24 | Wegovy | $26 |
| Lilly USA | Meals · 2025-04-17 | Mounjaro | $18 |
| Radius Health | Meals · 2025-04-14 | Tymlos | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-10 | Jardiance | $28 |
| Ascendis Pharma Endocrinology | Meals · 2025-04-01 | Yorvipath | $28 |
| Novo Nordisk | Meals · 2025-03-28 | Ozempic | $27 |
| Amgen | Meals · 2025-03-26 | Repatha | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-20 | Jardiance | $29 |
| Sanofi-Aventis U.S. | Meals · 2025-03-17 | Tzield | $20 |
| Amgen | Meals · 2025-03-13 | Evenity | $31 |
| Lilly USA | Meals · 2025-03-10 | Zepbound | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-06 | Kerendia | $29 |
| Mannkind | Meals · 2025-03-03 | Afrezza | $19 |
| Lilly USA | Meals · 2025-02-28 | Jardiance | $25 |
| Amgen | Meals · 2025-02-24 | Repatha | $23 |
| Novo Nordisk | Meals · 2025-02-22 | Ozempic | $21 |
| Radius Health | Meals · 2025-02-19 | Tymlos | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-07 | Kerendia | $28 |
| Abbott Laboratories | Meals · 2025-02-07 | Freestyle Libre 3 | $21 |
| Amgen | Education · 2025-01-31 | Tepezza | $10 |
| Amgen | Meals · 2025-01-31 | Tepezza | $10 |
| Medtronic | Meals · 2025-01-27 | Minimed 780g | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-23 | Jardiance | $23 |
| Radius Health | Meals · 2025-01-22 | Tymlos | $28 |
| Amgen | Meals · 2025-01-14 | Repatha | $26 |
| Dexcom | Meals · 2025-01-14 | Dexcom G6 Transmitter | $23 |
| Kyowa Kirin | Meals · 2025-01-09 | Crysvita | $26 |
| Amgen | Meals · 2025-01-06 | Tepezza | $30 |
See earlier years (2024, 2023, 2020)
2024: $2,399
| Amgen | Repatha | $543 | 22 payments
|
| Lilly USA | Mounjaro | $466 | 17 payments
|
| Beta Bionics | Ilet Bionic Pancreas | $237 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $192 | 8 payments
|
| Novo Nordisk | Ozempic | $185 | 9 payments
|
| Radius Health | Tymlos | $112 | 5 payments
|
| Dexcom | Dexcom G6 Transmitter | $82 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $73 | 3 payments
|
| Sanofi-Aventis U.S. | Tzield | $73 | 3 payments
|
| Mannkind | Afrezza | $72 | 3 payments
|
| Ascensia Diabetes Care Us | Eversense E3 Sensor Kit - Retail | $57 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $57 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $56 | 3 payments
|
| Kyowa Kirin | Crysvita | $50 | 2 payments
|
| Neurocrine Biosciences | None | $30 | 1 payment
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $29 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $24 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $20 | 1 payment
|
| Acella Pharmaceuticals | NP Thyroid 60 | $20 | 1 payment
|
| Vivus | Qsymia | $19 | 1 payment
|
2023: $1,397
| Lilly USA | Mounjaro | $262 | 9 payments
|
| Radius Health | Tymlos | $184 | 7 payments
|
| Novo Nordisk | Rybelsus | $178 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $119 | 5 payments
|
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $114 | 3 payments
|
| Embecta | Bd Nano 2nd Gen Pen Needle | $79 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $79 | 3 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $78 | 4 payments
|
| MannKind | Afrezza | $49 | 2 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $40 | 2 payments
|
| CeQur | Cequr Simplicity | $36 | 1 payment
|
| Medtronic | Minimed 780g | $27 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $25 | 1 payment
|
| IBSA Pharma | Licart | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $24 | 1 payment
|
| AbbVie | Synthroid | $21 | 1 payment
|
| Ascendis Pharma | Skytrofa | $21 | 1 payment
|
| Pfizer | Somavert | $20 | 1 payment
|
| Recordati Rare Diseases Inc. | Signifor Lar | $19 | 1 payment
|
2020: $147
| Medtronic MiniMed | Minimed 630g | $147 | 1 payment
|
Professional record
- NPI
- 1801055900
- Licence
- CA A125229California A125229: Current · expires 2027-04-30
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 2204 Grant Rd Ste 103, Mountain View, CA, 94040
- NPI first listed
- 2008-06-03
- NPI last updated
- 2025-02-10
- NPI record certified
- 2025-02-10
This is when the NPI record was last certified, not a medical board exam.